Mosaic ImmunoEngineering Inc.

CPMVdata completeness 63%15 fiscal years on file

Data notes: no data for concept 'revenue'; no data for concept 'totalDebt'

i. The business — what you’d actually own

Figure	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	—	—	—	—	—
Net income	−$3.68M¹	−$2.38M²	−$1.01M³	−$921,983⁴	−$687,846⁴
Operating cash flow	−$679,236⁵	−$690,129⁶	−$497,467⁷	−$241,159⁸	−$111,397⁸
Capital expenditure	—	—	—	—	—
Free cash flow (derived)	—	—	—	—	—
Total debt	—	—	—	—	—
Cash & equivalents	$226,142⁹	$220,645¹⁰	$156,178¹¹	$115,019¹²	$3,622¹²
Diluted shares	6.7M	7.2M	7.2M	7.2M	7.2M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

−$10.33

your share of equity

Profit it earned you last year

−$0.95

Free cash flow it threw off

—

Debt you’d be carrying

—

10 shares is a claim on −$10.33 of net worth that earned you −$0.95 last year.

iii. Is this a good business?

Moat signal · return on equity

— avg · 5y

Not enough data in the filings for a return-on-capital reading.

Management signal · capital allocation

+8% shares · 5y

Share count is up 8% over 5 years — owners have been diluted. Worth asking what they got for it.

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts